Ujin Pharma Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹0(0.00%)
Premium (ELP)
Ujin Pharma Limited's is preparing to launch its Initial Public Offering (IPO) with a substantial issue size of 1,91,51,400 Shares. The offering comprises a fresh issue component of 1,18,69,100 Shares.
The price band for the IPO has been set at TBD, providing investors with a range to place their bids. The minimum investment lot consists of TBD, making it accessible to both retail and institutional investors.
The subscription window for this public offering opens on TBD and will conclude on TBD. Following the subscription period, the share allotment is scheduled for TBD, with the official listing expected to commence on TBD on the NSE, BSE exchange.
Ujin Pharma Limited, incorporated in May 2024, is engaged in the trading and distribution of solvents, specialty chemicals, acids, monomers, pharmaceutical raw materials and nutraceuticals. The company serves customers across various industries, including pharmaceuticals, agrochemicals, petrochemicals, automotive, paints and coatings, printing inks, packaging and other industrial sectors. Building on more than two decades of industry experience through its predecessor partnership firm, the company has established a sourcing network of 1,277 suppliers and operates warehouses in Bhiwandi, Maharashtra, and Kandla, Gujarat. Across the last three financial years and the period ended December 31, 2025, it supplied approximately 8.53 lakh metric tonnes of chemical products to more than 3,000 customers. Through its subsidiary, Shiv Shakti Oxalate Private Limited (SSOPL), Ujin Pharma has expanded into value-added chemical processing, including solvent recycling, solvent recovery and printing chemical manufacturing. SSOPL operates a manufacturing facility at Kurkumbh, Pune, equipped with distillation, extraction, blending, storage and laboratory testing facilities. As of March 31, 2026, the company had 73 employees across management, finance, operations, logistics, sales, compliance, production, quality and safety functions.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
The expected premium (GMP) is based on market buzz and unofficial trading. It should not be considered as the guaranteed listing price. Always refer to the RHP and seek advice from a financial expert before making investment decisions.
💡 Read our detailed guide: What is IPO Grey Market Premium (GMP) & How It Works?•📈 Track all live rates on IPO GMP Today
- Diversified Chemical Product Portfolio: Ujin Pharma Limited imports, distributes, and supplies solvents, specialty chemicals, acids, monomers, pharmaceutical raw materials, and nutraceutical ingredients. Its broad product range allows it to serve pharmaceutical, agrochemical, and other industrial customers.
- Established Supplier & Customer Network: The company has developed relationships with suppliers and customers across multiple industries and geographical markets. Its distribution network across India and export presence support product accessibility and business expansion.
- Value-Added Business Opportunities: Through its subsidiary, the company is involved in solvent recycling and recovery, along with the manufacturing of printing chemicals. Its plans to expand into pharmaceutical and agrochemical intermediates may create opportunities to diversify operations and increase value addition.
- Low Profit Margins & Working Capital Requirements: Chemical distribution generally operates on thin margins and requires substantial funds for inventory, logistics, and customer credit. Higher borrowing costs or delayed customer payments may affect profitability and cash flow.
- Customer & Product Concentration: A significant portion of revenue comes from a limited number of major customers and selected products, including methanol and toluene. Any reduction in demand or loss of key customers could adversely affect business performance.
- Raw Material & Import Risks: The company depends partly on imported chemicals and external suppliers. Fluctuations in foreign exchange rates, international chemical prices, transportation costs, or supply-chain disruptions may increase operating expenses and reduce margins.
- Jinesh Rasiklal Sheth
- Umang Ketan Mehta
- Neha Umang Mehta
Ujin Pharma Limited
Kfin Technologies Limited